Related Experiment Video

Updated: May 1, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition

Alessia Lodi1, Sarah M Woods, Sabrina M Ronen

  • 1Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA.

NMR in Biomedicine
|April 8, 2014
PubMed

Insights

Metabolic reprogramming in cancer is key. MEK inhibition impacts cellular metabolism differently across cancer types, affecting phosphocholine, glucose uptake, and lactate production, offering insights into therapy response biomarkers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Metabolic reprogramming is a recognized hallmark of cancer.
  • Metabolic alterations can serve as predictive biomarkers for therapeutic response.
  • Mitogen-activated protein kinase kinase (MEK) inhibitors are a therapeutic strategy in oncology.

Purpose of the Study:

  • To investigate the metabolic consequences of MEK inhibition detectable by magnetic resonance spectroscopy (MRS).
  • To assess changes in phosphocholine, glucose uptake, and lactate production in response to MEK inhibition.
  • To explore the cell-line-dependent effects of MEK inhibition on cancer cell metabolism.

Main Methods:

  • Utilized MRS to detect metabolic changes in PC3 prostate cancer, MCF-7 breast cancer, and A375 melanoma cell lines.
  • Administered U0126, a MEK inhibitor, to treated cell lines.
  • Quantified levels of phosphocholine, glucose uptake, and lactate production.

Main Results:

  • MEK inhibition significantly decreased phosphocholine levels across all tested cell lines, mediated by reduced choline kinase α expression.
  • Glycolytic response to MEK inhibition was cell-line dependent: A375 cells showed decreased glucose uptake and lactate production, while PC3 and MCF-7 cells showed increased uptake and production.
  • Observed metabolic changes in PC3 and MCF-7 cells were linked to the activation of the phosphoinositide 3-kinase and AMP-activated protein kinase pathways.

Conclusions:

  • Non-invasive MRS methods can provide valuable information on cellular metabolism following MEK inhibition.
  • Metabolic readouts can indicate the activation of feedback loops and serve as biomarkers for MEK inhibitor therapy.
  • Understanding cell-specific metabolic responses to MEK inhibition is crucial for optimizing cancer treatment strategies.
Keywords:
MEKMRSU0126metabolism

More Related Videos

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence09:58

An Efficient Protocol to Assess ERK Activity Modulation in Early Zebrafish Noonan Syndrome Models via Live FRET Microscopy and Immunofluorescence

Published on: May 2, 2025

864
Assaying Protein Kinase Activity with Radiolabeled ATP08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

18.0K

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K